In a patient with confirmed hepatitis E infection and a history of psoriasis who is re-admitted with vomiting, abdominal pain, and liver tenderness, what laboratory and imaging studies are indicated and what is the appropriate management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Diagnostic Testing and Management for Hepatitis E Re-admission

In this hepatitis E positive patient with psoriasis presenting with vomiting, abdominal pain, and liver tenderness, immediately obtain HEV RNA (PCR), liver function tests (ALT, AST, bilirubin, INR), complete blood count with platelets, renal function with urinalysis, and abdominal ultrasound to assess for acute-on-chronic liver failure, chronic HEV infection, or extrahepatic complications. 1

Critical Initial Assessment

Immediate Laboratory Testing Required:

Hepatitis E Specific Tests:

  • HEV RNA by PCR (blood and stool) - essential to determine if this is persistent/chronic infection (RNA positive >3 months) or reactivation 1
  • Anti-HEV IgM and IgG - though serology may be negative in immunosuppressed states 1
  • HEV viral load - to establish baseline for monitoring 1

Liver Function Monitoring:

  • ALT, AST, bilirubin, INR - monitor for progression to acute liver failure 1
  • Albumin, total protein - assess synthetic function
  • Complete metabolic panel - evaluate for complications

Critical Safety Parameters:

  • Complete blood count with differential - check for thrombocytopenia (reported complication) 1
  • Renal function (creatinine, BUN) with urinalysis - screen for proteinuria/glomerulonephritis (HEV-associated extrahepatic manifestation) 1
  • Coagulation profile (PT/INR) - essential for detecting acute liver failure 1

Imaging Studies:

Abdominal ultrasound - evaluate for:

  • Hepatomegaly, liver echogenicity changes
  • Biliary obstruction (though less likely given clinical picture)
  • Ascites or other complications 2

Key Clinical Considerations

Psoriasis Connection - Critical Risk Factor:

This patient's psoriasis history is highly relevant. If they are on or have recently received immunosuppressive therapy (particularly rituximab, methotrexate, or other anti-CD20 agents), they are at substantial risk for:

  • Chronic HEV infection (defined as HEV RNA positive >3 months) 3, 4
  • Treatment-resistant hepatitis E 3
  • False-negative serology (antibodies may be undetectable in immunosuppressed patients, making RNA testing mandatory) 1

Differential Diagnosis to Exclude:

Given the clinical presentation, also test for:

  • Drug-induced liver injury (DILI) - 13% of suspected DILI cases are actually hepatitis E 1
  • Other viral hepatitis (HAV, HBV, HCV, EBV, CMV) - particularly with ALT >1000 U/L 2, 5, 6
  • Autoimmune hepatitis - can coexist with psoriasis 7
  • Pancreatitis - check lipase/amylase as HEV can cause acute pancreatitis 8

Management Algorithm

For Immunocompetent Patients (No Immunosuppression):

Supportive care is the mainstay:

  • Monitor ALT, AST, bilirubin, INR regularly (at least weekly initially) 1
  • Symptomatic treatment for nausea/vomiting (antiemetics, IV fluids as needed) 9
  • No specific antiviral therapy required - acute HEV typically self-resolves in immunocompetent patients 1
  • Watch for acute liver failure - rare but reported in 10% of ALF cases in some series 1

For Immunosuppressed Patients (On Psoriasis Treatment):

This requires aggressive intervention:

  1. Reduce or discontinue immunosuppression if medically feasible 3, 4

  2. If HEV RNA remains positive at 3 months = chronic infection:

    • Initiate ribavirin therapy (typical dose 600-800 mg/day, adjusted for renal function) 3, 4
    • Monitor HEV RNA viral load to assess treatment response 1
    • Continue until sustained virological response achieved 3

  3. Monitor for treatment resistance - particularly in anti-CD20 therapy patients 3

Special Monitoring for Extrahepatic Complications:

  • Neurological symptoms (Guillain-Barré syndrome, encephalitis, neuralgic amyotrophy) - test HEV regardless of liver enzymes if present 1
  • Proteinuria - check urinalysis; if positive, consider renal biopsy for HEV-associated glomerulonephritis 1
  • Severe thrombocytopenia - monitor platelet count 1
  • Cryoglobulinemia - if arthralgia, myalgia, rash develop 1

Common Pitfalls to Avoid

  1. Do NOT assume this is just DILI from psoriasis medications - 13% of presumed DILI is actually hepatitis E 1, 5

  2. Do NOT rely solely on serology in immunosuppressed patients - antibodies may be absent; HEV RNA testing is mandatory 1

  3. Do NOT delay HEV RNA testing - it should be part of first-line investigation, not after other tests are negative 1

  4. Do NOT overlook chronic infection risk - if immunosuppressed and HEV RNA positive, plan 3-month follow-up testing to define chronicity 1

  5. Do NOT miss extrahepatic manifestations - check for neurological symptoms, proteinuria, and thrombocytopenia even if liver enzymes are only mildly elevated 1

Follow-up Strategy

  • Repeat HEV RNA at 3 months if initially positive to rule out chronic infection 1
  • Serial liver function tests until normalization 1
  • Recheck renal function and urinalysis if any proteinuria detected 1
  • Consider hepatology referral if evidence of chronic infection, severe acute hepatitis, or underlying chronic liver disease 1

References

Related Questions

Should hepatitis E serology be repeated in a patient with confirmed hepatitis E, psoriasis on immunosuppressants, now presenting with vomiting, abdominal pain, and liver tenderness?
What is the appropriate evaluation and management for a patient presenting with abdominal pain and elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT)?
What is the appropriate evaluation and management for a patient with normal bilirubin and markedly elevated AST and ALT?
What is the appropriate management of cholestatic hepatitis in a patient with psoriasis?
How should a 2‑month‑old infant with viral hepatitis, markedly elevated transaminases, normal bilirubin, normal coagulation profile, normal albumin, normal glucose, normal abdominal ultrasound, neutropenia with reactive lymphocytosis, and who has been receiving ampicillin, cefotaxime, and acyclovir for four days be managed given persistent transaminase elevation and worsening neutropenia without any clinical symptoms?
Can baclofen be prescribed for a patient with heart failure, and what precautions and alternative therapies should be considered?
What is the appropriate dose of trazodone for a 25‑lb (approximately 11.3 kg) dog?
In a young male with a three‑day fever about 20 days ago, now presenting with asymmetric, non‑migratory small‑joint inflammatory arthritis and paraspinal muscle spasm without spinal tenderness, what is the recommended initial work‑up and management?
What is the recommended method and dosage for converting levothyroxine from oral (by mouth) to intravenous administration?
Which classes of antihypertensive drugs are known to trigger bullous pemphigoid?
Should hepatitis E serology be repeated in a patient with confirmed hepatitis E, psoriasis on immunosuppressants, now presenting with vomiting, abdominal pain, and liver tenderness?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.